Illustration: Sarah Grillo/Axios. Stock: Getty Images
Polyphron raised a $20 million seed to develop human tissue models for drug development, CEO Matthew Osman tells Axios exclusively.
Why it matters: AI can identify promising drug candidates, but researchers still need to determine whether those predictions hold up in human biology.
